ABOS
Acumen Pharmaceuticals, Inc.
Recent 8-K filings for ABOS
Each filing is summarized by an LLM — headline, three bullets, event type. The source document on EDGAR is one click away. See methodology.
-
May 12, 2026 11:07 UTC earnings item 2.02item 7.01item 9.01
Acumen posts Q1 net loss $20.7M; Phase 2 AD topline results expected late 2026
source · ABOS on sec.gov